you are here: HomeNewsBiocon
biocon
Jump to
1508 Results Found
  • Mylan-Biocon's breast cancer biosimilar gets ANVISA nod Dec 29, 2017 02:43 PM IST

    Mylan-Biocon's breast cancer biosimilar gets ANVISA nod

    Biosimilar trastuzumab, indicated for breast cancer treatment, has been co-developed by Biocon and Mylan.

  • Market Update: CNX Auto rallies as Maruti, Hero Moto jumps 4%, Jain Irrigation zooms over 10%; HUL, Biocon hit 52-week high Dec 19, 2017 03:07 PM IST

    Market Update: CNX Auto rallies as Maruti, Hero Moto jumps 4%, Jain Irrigation zooms over 10%; HUL, Biocon hit 52-week high

    The market breadth was in favour of the advances on Tuesday afternoon with 1308 stocks advancing as against 383 declines while 298 remained unchanged. On the other hand, 1831 stocks advanced and 775 stocks declined while 175 remained unchanged on the BSE.

  • Biocon creates new subsidiary to unlock value of its biologics business Dec 05, 2017 12:05 PM IST

    Biocon creates new subsidiary to unlock value of its biologics business

    The biologics business consists biosimilars that include monoclonal antibodies and recombinant insulins and novel biologics

  • Biocon surges 14% after US FDA gives approval to biosimilar version of Herceptin Dec 04, 2017 09:18 AM IST

    Biocon surges 14% after US FDA gives approval to biosimilar version of Herceptin

    Mylan and Biocon said that USFDA approved Mylan’s Ogivri, a biosimilar to Swiss biotech giant Roche's blockbuster cancer drug Herceptin, co-developed with Biocon.

  • Biocon shares gain after Mylan gets EMA nod for biosimilars Dec 02, 2017 10:00 AM IST

    Biocon shares gain after Mylan gets EMA nod for biosimilars

    The shares of Biocon opened at Rs 445, then surged 3.92 percent to touch an intra-day high of Rs 449.20 and finally settled for the day at Rs 446.55, up 3.31 percent over its previous closing price

  • Biocon says cancer biosimilar Bevacizumab launch to boost India branded biz Nov 23, 2017 05:55 PM IST

    Biocon says cancer biosimilar Bevacizumab launch to boost India branded biz

    The market size for Bevacizumab, both innovator product and biosimilars, in India is estimated at Rs 177 Crore (USD 27 million), according to IPSOS June MAT 2017 data.

  • Biocon introduces oncologic biosimilar KRABEVA in India Nov 23, 2017 01:39 PM IST

    Biocon introduces oncologic biosimilar KRABEVA in India

    The biosimilar product will be used for the treatment of patients with metastatic colorectal cancer and other types of lung, kidney, cervical, ovarian and brain cancers in India, Biocon said in a filing to the BSE.

  • Getting EIR from USFDA for Bengaluru unit a positive news: Biocon Nov 20, 2017 01:22 PM IST

    Getting EIR from USFDA for Bengaluru unit a positive news: Biocon

    The company has been told that the May inspection has been closed and they can carry on CAPA implementation, said Kiran Mazumdar Shaw, CMD, Biocon.

  • Biocon facility gets inspection closure report from USFDA Nov 20, 2017 10:22 AM IST

    Biocon facility gets inspection closure report from USFDA

    "The US Food and Drug Administration (USFDA) has issued an Establishment Inspection Report in relation to the cGMP (current good manufacturing practice) inspection of its aseptic drug product facility that was audited between May 25 -June 3, 2017," Biocon said in a BSE filing.

  • Biocon arm widens partnership terms with Bristol-Myers Squibb Nov 14, 2017 10:40 AM IST

    Biocon arm widens partnership terms with Bristol-Myers Squibb

    The company today said the expanded scope of partnership also includes addition of a new facility and ramping up the team of scientists working for it.

  • Buy Biocon; target of Rs 410: Axis Direct Nov 09, 2017 11:17 AM IST

    Buy Biocon; target of Rs 410: Axis Direct

    Axis Direct is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 410 in its research report dated November 02, 2017.

  • Optimistic about entry into generics market; hoping for better returns in H2: Biocon Oct 27, 2017 12:53 PM IST

    Optimistic about entry into generics market; hoping for better returns in H2: Biocon

    In an interview to CNBC-TV18, Kiran Mazumdar Shaw, Chairperson & MD of Biocon spoke about the results and her outlook for the company.

  • Biocon Q2 PAT may dip 27.2% YoY to Rs. 107.1 cr: Kotak Oct 13, 2017 05:40 PM IST

    Biocon Q2 PAT may dip 27.2% YoY to Rs. 107.1 cr: Kotak

    Net Sales are expected to increase by 8.4 percent Y-o-Y (up 9.1 percent Q-o-Q) to Rs. 1018.9 crore, according to Kotak.

  • Buy Hexaware Technologies, Biocon: Sandeep Wagle Oct 10, 2017 03:56 PM IST

    Buy Hexaware Technologies, Biocon: Sandeep Wagle

    Sandeep Wagle of powermywealth.com suggests buying Hexaware Technologies and Biocon.

  • Go long in Apollo Hospitals, Biocon: Prakash Gaba Oct 10, 2017 03:01 PM IST

    Go long in Apollo Hospitals, Biocon: Prakash Gaba

    Prakash Gaba of prakashgaba.com is of the view that one can go long in Apollo Hospitals and Biocon.

  • USFDA issues CRL for proposed biosimilar Pegfilgrastim: Biocon Oct 10, 2017 02:20 PM IST

    USFDA issues CRL for proposed biosimilar Pegfilgrastim: Biocon

    This product is a part of the biosimilars portfolio being developed jointly by Biocon and Mylan. "The US Food and Drug Administration has issued a CRL for Mylan's Biologics License Application (BLA) for MYL-1401H, a proposed biosimilar Pegfilgrastim", Biocon spokesperson said in a statement.

  • Biocon gets CRL from USFDA for anti-cancer drug Oct 10, 2017 11:46 AM IST

    Biocon gets CRL from USFDA for anti-cancer drug

    The company, however said it does not expect this CRL to impact the commercial launch timing of biosimilar Pegfilgrastim in the US. This product is a part of the biosimilars portfolio being developed jointly by Biocon and Mylan.

  • Buy Prestige Estates, MOIL, TVS Motor, Kotak Mahindra Bank, Bata India: Ashwani Gujral Oct 10, 2017 11:13 AM IST

    Buy Prestige Estates, MOIL, TVS Motor, Kotak Mahindra Bank, Bata India: Ashwani Gujral

    Ashwani Gujral of ashwanigujral.com recommends buying Prestige Estates, MOIL, TVS Motor, Kotak Mahindra Bank and Bata India.

  • It wouldn't be wise to change Biocon's EPS estimate with CRL received: Nirmal Bang Oct 10, 2017 11:04 AM IST

    It wouldn't be wise to change Biocon's EPS estimate with CRL received: Nirmal Bang

    In an interview to CNBC-TV18, Vishal Manchanda, Pharma Analyst at Nirmal Bang Institutional Equities shared his views and readings on the news as well as on Biocon stock.

  • Market update: Nifty in green led by pharma & IT; Lupin, Biocon, Adani Transmission rally Oct 10, 2017 10:36 AM IST

    Market update: Nifty in green led by pharma & IT; Lupin, Biocon, Adani Transmission rally

    Siyaram Silk, HEG Limited, Jindal Worldwide, Goa Carbon and VIP Industries were the stocks that hit 52-week high in the Nifty while within the BSE Index, stocks like Gillette India, Kotak Mahindra Bank, Bharat Financial, Bata India, Tata Steel, TVS Motor and TVS Electronics hit 52-week high in today's trade.

  • Biocon's cancer drug Pegfilgrastim: US FDA to give final view today Oct 09, 2017 03:21 PM IST

    Biocon's cancer drug Pegfilgrastim: US FDA to give final view today

    Biocon is under pressure today. The target action date for cancer drug pegfilgrastim is today.

  • I don't give much thought to rich list: Kiran Mazumdar-Shaw Oct 06, 2017 01:58 PM IST

    I don't give much thought to rich list: Kiran Mazumdar-Shaw

    The chairperson and managing director of Bengaluru- headquartered Biocon Ltd, with a fortune of USD 2.16 billion, was placed at the 72nd position on Forbes magazine's annual 'India Rich List 2017'.

  • Buy Biocon, Bajaj Auto; sell Indo Count Industries: Sudarshan Sukhani Sep 21, 2017 02:27 PM IST

    Buy Biocon, Bajaj Auto; sell Indo Count Industries: Sudarshan Sukhani

    Sudarshan Sukhani of s2analytics.com is of the view that one can buy Biocon and Bajaj Auto and can sell Indo Count Industries.

  • Divis Labs, Dr Reddy's, Aurobindo Pharma, Biocon, Lupin to get astro support: Gupta Sep 21, 2017 11:56 AM IST

    Divis Labs, Dr Reddy's, Aurobindo Pharma, Biocon, Lupin to get astro support: Gupta

    Divis Laboratories, Dr Reddy's Laboratories, Aurobindo Pharma, Biocon and Lupin will get astrological support, says Satish Gupta of astrostocktips,

  • Buy Titan Company, Eicher Motors, Biocon, Dr Reddy's Labs, IDFC: VK Sharma Sep 19, 2017 10:07 AM IST

    Buy Titan Company, Eicher Motors, Biocon, Dr Reddy's Labs, IDFC: VK Sharma

    VK Sharma, Head - PCG and Capital Market Strategy at HDFC Securities suggests buying Titan Company, Eicher Motors, Biocon, Dr Reddy's Labs and IDFC.

Sections